candesartan has been researched along with Chronic Kidney Failure in 23 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we examined the effects of the ANG II receptor type 1 (AT1R) blockade using candesartan on long-term renal molecular and functional changes in response to partial unilateral ureteral obstruction (PUUO)." | 7.74 | Candesartan prevents long-term impairment of renal function in response to neonatal partial unilateral ureteral obstruction. ( Djurhuus, JC; Frøkiaer, J; Jørgensen, TM; Knepper, M; Nielsen, S; Nørregaard, R; Pedersen, M; Topcu, SO; Wang, G, 2007) |
| " Beginning 8 wk after birth, SHR underwent unilateral nephrectomy and were given vehicle (control), or candesartan at a standard 5 mg/kg per d (T5), high 25 mg/kg per d (T25), or ultrahigh 75 mg/kg per d dosage (T75)." | 5.34 | Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. ( Dworkin, LD; Gong, R; Rifai, A; Tolbert, EM; Yu, C, 2007) |
| " Here, we examined the effects of the ANG II receptor type 1 (AT1R) blockade using candesartan on long-term renal molecular and functional changes in response to partial unilateral ureteral obstruction (PUUO)." | 3.74 | Candesartan prevents long-term impairment of renal function in response to neonatal partial unilateral ureteral obstruction. ( Djurhuus, JC; Frøkiaer, J; Jørgensen, TM; Knepper, M; Nielsen, S; Nørregaard, R; Pedersen, M; Topcu, SO; Wang, G, 2007) |
| "Standard ACEI plus candesartan is more effective in reducing systolic blood pressure and proteinuria than a 50% increase in ACEI dose." | 3.72 | Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure. ( Fairley, KF; Kincaid-Smith, P; Packham, D, 2004) |
| "Rats with adenine-induced chronic renal failure (A-CRF) develop metabolic and cardiovascular abnormalities resembling those in patients with chronic kidney disease." | 1.39 | Rats with adenine-induced chronic renal failure develop low-renin, salt-sensitive hypertension and increased aortic stiffness. ( Carlström, M; Grimberg, E; Guron, G; Johansson, ME; Lundberg, JO; Lundgren, J; Nguy, L; Nilsson, H; Teerlink, T, 2013) |
| "In end-stage renal disease (ESRD) the incidence of genomic damage is increased." | 1.37 | AT1 receptor antagonist candesartan attenuates genomic damage in peripheral blood lymphocytes of patients on maintenance hemodialysis treatment. ( Bahner, U; Grupp, C; Heidland, A; Klassen, A; Rutkowski, P; Schupp, N; Sebeková, K; Stopper, H, 2011) |
| " Beginning 8 wk after birth, SHR underwent unilateral nephrectomy and were given vehicle (control), or candesartan at a standard 5 mg/kg per d (T5), high 25 mg/kg per d (T25), or ultrahigh 75 mg/kg per d dosage (T75)." | 1.34 | Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. ( Dworkin, LD; Gong, R; Rifai, A; Tolbert, EM; Yu, C, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.70) | 18.2507 |
| 2000's | 16 (69.57) | 29.6817 |
| 2010's | 5 (21.74) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nguy, L | 1 |
| Johansson, ME | 1 |
| Grimberg, E | 1 |
| Lundgren, J | 1 |
| Teerlink, T | 1 |
| Carlström, M | 1 |
| Lundberg, JO | 1 |
| Nilsson, H | 1 |
| Guron, G | 1 |
| Cao, X | 1 |
| Nakamura, Y | 1 |
| Wada, T | 1 |
| Izumi-Nakaseko, H | 1 |
| Ando, K | 1 |
| Sugiyama, A | 1 |
| Suzuki, H | 2 |
| Kanno, Y | 2 |
| Sugahara, S | 1 |
| Ikeda, N | 1 |
| Shoda, J | 1 |
| Takenaka, T | 2 |
| Inoue, T | 1 |
| Araki, R | 1 |
| Shigenaga, A | 1 |
| Tamura, K | 1 |
| Dejima, T | 1 |
| Ozawa, M | 1 |
| Wakui, H | 1 |
| Masuda, S | 1 |
| Azuma, K | 1 |
| Tsurumi-Ikeya, Y | 1 |
| Mitsuhashi, H | 1 |
| Okano, Y | 1 |
| Kokuho, T | 1 |
| Sugano, T | 1 |
| Ishigami, T | 1 |
| Toya, Y | 1 |
| Uchino, K | 1 |
| Tokita, Y | 1 |
| Umemura, S | 1 |
| Schorn, R | 1 |
| Gaspert, A | 1 |
| Cohen, CD | 1 |
| Schupp, N | 1 |
| Rutkowski, P | 1 |
| Sebeková, K | 1 |
| Klassen, A | 1 |
| Bahner, U | 1 |
| Grupp, C | 1 |
| Heidland, A | 1 |
| Stopper, H | 1 |
| Marson, BP | 1 |
| Poli de Figueiredo, CE | 1 |
| Tanus-Santos, JE | 1 |
| Ueno, T | 1 |
| Kaname, S | 1 |
| Takaichi, K | 1 |
| Nagase, M | 1 |
| Tojo, A | 1 |
| Onozato, ML | 1 |
| Fujita, T | 1 |
| Matsuda, H | 1 |
| Hayashi, K | 1 |
| Homma, K | 1 |
| Yoshioka, K | 1 |
| Kanda, T | 1 |
| Takamatsu, I | 1 |
| Tatematsu, S | 1 |
| Wakino, S | 1 |
| Saruta, T | 1 |
| Kincaid-Smith, P | 1 |
| Fairley, KF | 1 |
| Packham, D | 1 |
| Phakdeekitcharoen, B | 1 |
| Leelasa-nguan, P | 1 |
| Kim, EJ | 1 |
| Jung, YW | 1 |
| Kwon, TH | 1 |
| Nakamura, T | 2 |
| Takahashi, A | 1 |
| Takase, H | 1 |
| Toriyama, T | 1 |
| Sugiura, T | 1 |
| Kurita, Y | 1 |
| Ueda, R | 1 |
| Dohi, Y | 1 |
| Furuya, R | 1 |
| Odamaki, M | 1 |
| Kumagai, H | 1 |
| Hishida, A | 1 |
| Topcu, SO | 1 |
| Pedersen, M | 1 |
| Nørregaard, R | 1 |
| Wang, G | 1 |
| Knepper, M | 1 |
| Djurhuus, JC | 1 |
| Nielsen, S | 1 |
| Jørgensen, TM | 1 |
| Frøkiaer, J | 1 |
| Almirall, J | 1 |
| Valenzuela, MP | 1 |
| Lopez, T | 1 |
| Yu, C | 1 |
| Gong, R | 1 |
| Rifai, A | 1 |
| Tolbert, EM | 1 |
| Dworkin, LD | 1 |
| García Donaire, JA | 1 |
| Ruilope, LM | 1 |
| Nishimura, M | 1 |
| Takahashi, H | 1 |
| Yoshimura, M | 1 |
| Obata, J | 1 |
| Kimura, H | 1 |
| Ohno, S | 1 |
| Yoshida, Y | 1 |
| Kawachi, H | 1 |
| Shimizu, F | 1 |
| Shibasaki, Y | 1 |
| Mori, Y | 1 |
| Tsutumi, Y | 1 |
| Masaki, H | 1 |
| Sakamoto, K | 1 |
| Murasawa, S | 1 |
| Maruyama, K | 1 |
| Moriguchi, Y | 1 |
| Tanaka, Y | 1 |
| Iwasaka, T | 1 |
| Inada, M | 1 |
| Matsubara, H | 1 |
| Taal, MW | 1 |
| Chertow, GM | 1 |
| Rennke, HG | 1 |
| Gurnani, A | 1 |
| Jiang, T | 1 |
| Shahsafaei, A | 1 |
| Troy, JL | 1 |
| Brenner, BM | 1 |
| Mackenzie, HS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00530595] | 0 participants | Interventional | Completed | ||||
| Effect of Nighttime Valsartan on Prognosis of Nocturnal Hypertension Patients Undergoing Maintenance Hemodialysis[NCT03594825] | Phase 4 | 68 participants (Anticipated) | Interventional | 2018-11-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for candesartan and Chronic Kidney Failure
| Article | Year |
|---|---|
Imbalanced matrix metalloproteinases in cardiovascular complications of end-stage kidney disease: a potential pharmacological target.
Topics: Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Doxycycline; Humans; K | 2012 |
Angiotensin receptor blockade in diabetic renal disease--focus on candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Clinica | 2007 |
6 trials available for candesartan and Chronic Kidney Failure
| Article | Year |
|---|---|
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2008 |
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2008 |
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2008 |
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2008 |
Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphen | 2009 |
Differing anti-proteinuric action of candesartan and losartan in chronic renal disease.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidaz | 2003 |
Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidaz | 2004 |
An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C | 2005 |
Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases | 2006 |
15 other studies available for candesartan and Chronic Kidney Failure
| Article | Year |
|---|---|
Rats with adenine-induced chronic renal failure develop low-renin, salt-sensitive hypertension and increased aortic stiffness.
Topics: Adenine; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Arterial Pressure; Benzimidazoles; | 2013 |
L/N-type Ca
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calcium Channel Blocker | 2017 |
[Anti-RNA polymerase III antibodies in scleroderma renal crisis].
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2010 |
AT1 receptor antagonist candesartan attenuates genomic damage in peripheral blood lymphocytes of patients on maintenance hemodialysis treatment.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2011 |
LOX-1, an oxidized low-density lipoprotein receptor, was upregulated in the kidneys of chronic renal failure rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2003 |
Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2004 |
Angiotensin II AT1 receptor blockade changes expression of renal sodium transporters in rats with chronic renal failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aquaporin 2; Aquaporins; Benzimidazoles; Biphenyl | 2005 |
Impact of angiotensin II receptor blocker on plasma levels of adiponectin and advanced oxidation protein products in peritoneal dialysis patients.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Bipheny | 2006 |
Candesartan prevents long-term impairment of renal function in response to neonatal partial unilateral ureteral obstruction.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Aquaporin 2; Benzim | 2007 |
Candesartan reduces cardiovascular events in patients on chronic haemodialysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases | 2007 |
Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2007 |
Upregulation of the brain renin-angiotensin system in rats with chronic renal failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2007 |
Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1999 |
Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidaz | 1999 |
Mechanisms underlying renoprotection during renin-angiotensin system blockade.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Chemokine CCL2 | 2001 |